OXiGENE Announces Issuance of U.S. Patent for OXi4503 in Acute Myeloid Leukemia

By: via Benzinga
OXiGENE, Inc. (Nasdaq: OXGN), a biopharmaceutical company developing novel therapies for the treatment of cancer, today announced that ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.